Mid-dosing interval concentration of atazanavir and virological outcome in patients treated for HIV-1 infection.

Medicine and Dentistry

• Atazanavir 100%
• Patient 60%
• Human Immunodeficiency Virus 40%
• Therapeutic Drug Monitoring 40%
• Inpatient 40%
• Toxicity 20%
• Predictor 20%
• Hyperbilirubinemia 20%
• Bilirubin 20%
• Odds Ratio 20%
• Drug 20%
• Human Immunodeficiency Virus 1 Infection 20%
• Chemotherapeutic Agent 20%
• Monitoring 20%
• Plasma 20%
• Clinical Significance 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Atazanavir 100%
• HIV 40%
• Therapeutic Drug Monitoring 40%
• Hyperbilirubinemia 20%
• Toxicity 20%
• Bilirubin 20%
• Drug 20%
• Human Immunodeficiency Virus 1 Infection 20%
• Virus 20%

Immunology and Microbiology

• Human Immunodeficiency Virus 60%
• Blood Plasma 20%
• Sample 20%
• Virus 20%